The co-founder of Shanghai Genomics Co., Ltd. is a director, Representative Executive Officer, President and CEO of the Company and has over 20 years of biomedical research experience.
The company believes that improving management efficiency, soundness and transparency will increase long-term corporate value and support mutual prosperity with stakeholders, including shareholders. It identifies stronger corporate governance as a management priority.
GNI Group Inc. is a global healthcare company headquartered in Japan that, through its consolidated subsidiaries, operates an integrated business spanning drug discovery, manufacturing, and sales.
GNI Group Inc. (hereinafter, “the Company”) recognizes the importance of personal information obtained from its stakeholders and considers protecting it fundamental to the Group’s business activities and one of its most important management priorities.